Alkem Laboratories Limited has informed the Exchange about an update related to the completion of acquisition by the Company, of 100% stake of Adroit Biomed Limited ( Adroit ), a company incorporated in India.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Laboratories has informed the stock exchange that it has completed the acquisition of 100% stake in Adroit Biomed Limited, an India-incorporated company. This marks the formal closure of the deal announced earlier. Adroit Biomed will now operate as a wholly-owned subsidiary of Alkem Laboratories. The acquisition is expected to strengthen Alkem's presence in the bio-pharmaceuticals and skincare/derma segment, depending on Adroit's business focus.
This is a completed acquisition, meaning no further open offer trigger or shareholder action is required at this stage. The market may react based on the strategic fit and valuation paid, but the deal closure removes any lingering deal-risk overhang on the stock.